Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Expert Stresses Importance of Genetic Testing in Ovarian Cancer

July 12th 2018

Deborah Krakow, MD, discusses the value of a patient’s family history and its implications on genetic counseling.

Pietras Presents Pillars of Palliative Care in Ovarian Cancer

July 12th 2018

Christopher J. Pietras, MD, discusses the elements of palliative care for patients with ovarian cancer.

Antibody-Directed Therapeutic Research Ongoing in Ovarian Cancer

July 12th 2018

Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.

Expert Tracks the Activity of PARP Inhibitors in Ovarian Cancer

July 11th 2018

Gottfried E. Konecny, MD, discusses developments in the understanding of response to PARP inhibition in ovarian cancer.

Efforts Continue to Increase Immunotherapy Impact in Gynecologic Cancers

July 10th 2018

John A. Glaspy, MD, discusses challenges and progress with immunotherapy in gynecologic cancers.

Slamon Specifies Next Steps in Ovarian Cancer Treatment

July 3rd 2018

Dennis J. Slamon, MD, PhD, discusses new opportunities for treatment advances in ovarian cancer.

Addressing PARP Inhibitor Resistance in Ovarian Cancer

July 2nd 2018

Kelly McCann, MD, PhD, discusses the process of DNA damage and repair, resistance to PARP inhibitors, and rational combination strategies to overcome resistance.

Dr. Rao on Testing for Somatic and Germline Mutations

June 29th 2018

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses testing for somatic and germline mutations in patients with ovarian cancer.

Olaparib Improves PFS as Frontline Maintenance in Ovarian Cancer

June 27th 2018

Olaparib tablets reduced the risk of disease progression or death compared with placebo as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.

Ovarian Cancer Incidence, Mortality Decline But Access to Care Is Not Equal

June 26th 2018

Ovarian cancer incidence and mortality have declined significantly over the past few decades, but eliminating racial disparities in treatment and improving prevention and early detection could help save even more women.

Dr. Sasine on CAR T-Cell Therapy in Ovarian Cancer

June 25th 2018

Joshua P. Sasine, MD, medical director, Chimeric Antigen Receptor T-Cell Program, David Geffen School of Medicine, University of California, Los Angeles, discusses chimeric antigen receptor (CAR) T- cell therapy in ovarian cancer.

FDA Approves Bevacizumab as Frontline Ovarian Cancer Treatment After Surgery

June 13th 2018

The FDA has approved bevacizumab for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.

Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian Cancer

June 13th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the FDA approval of bevacizumab (Avastin) as a frontline treatment in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Dr. Cohen Discusses Surgery in Early-Stage Ovarian Cancer

June 12th 2018

Joshua G. Cohen, MD, assistant professor, Division of Gynecologic Oncology, University of California, Los Angeles, discusses surgery in patients with early-stage ovarian cancer.

Dr. O'Malley on the FORWARD II Phase Ib Study in Ovarian Cancer

June 12th 2018

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses the safety and efficacy results of the FORWARD II phase Ib study in patients with ovarian cancer.

Dr. Konecny Discusses the Role of PARP Inhibitors in Ovarian Cancer

June 7th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Glaspy on Immunogenicity in Ovarian Cancer

June 6th 2018

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles (UCLA) School of Medicine, discusses immunogenicity in ovarian cancer.

Dr. Rao on Improving Methods of Early Detection of Ovarian Cancer

June 6th 2018

Jianyu Rao, MD, professor and chief of Cytopathology, University of California, Los Angeles, discusses improving methods of early detection of ovarian cancer.

Dr. Bansal on Chemotherapeutic Approaches for Patients With Ovarian Cancer

June 4th 2018

Nisha Bansal, MD, gynecologic oncologist, University of California, Los Angeles, discusses frontline chemotherapeutic approaches for patients with ovarian cancer.

Dr. Pietras on Palliative Care for Patients With Ovarian Cancer

June 1st 2018

Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses palliative care for patients with ovarian cancer.